Grade: Pharmaceutical Grade

Factory Location: shan dong

Main Sales Markets: Asia

Monthly Production Capacity: 50kg

Contract Manufacturing: CRO,CMO

Packaging Information: 1-5kg/Cardboard bucket

Delivery Lead Time: 3-5 Day

Sample Provided: no

Payment Terms: LC/DP/OA/TT

On January 8, 2015, the United States FDA approved the anticoagulant drug Edoxaban from the Japanese pharmaceutical company DaiichiSankyo under the trade name Savaysa. Idoxaban is an oral Chemicalbook selective coagulation factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism, used to reduce the risk of stroke and systemic embolism events in patients with NVAF, currently available in 60mg, 30mg, and 15mg.